ATHE - יחס שווי חברה לקצב צמיחת הרווח Alterity Therapeutics Ltd.

The PEG ratio chart demonstrates the commercialization potential of neurotherapy through sales of the ATH434 drug for Alterity Therapeutics (ATHE). The value of 0.00 reflects the baseline level of the metric, while the active pipeline prepares for critical Phase II trial results. The company's strategy relies on capturing unique niches in the treatment of rare brain pathologies and Parkinson's disease.

To objectively evaluate Alterity Therapeutics (ATHE), a manager must compare the asset's market value with its earnings dynamics. The PEG ratio measures the P/E ratio relative to the projected earnings growth rate, where a value below one signals undervaluation. The PEG fundamental indicator on the GURU.Markets platform allows for tracking this balance dynamically. For a biotechnology company utilizing a full-outsourcing development model, this serves as a critical filter for operational risks.